PortfoliosLab logo
DNA vs. ARDX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DNA and ARDX is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

DNA vs. ARDX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Ardelyx, Inc. (ARDX). The values are adjusted to include any dividend payments, if applicable.

-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2025FebruaryMarchApril
-98.06%
-40.26%
DNA
ARDX

Key characteristics

Sharpe Ratio

DNA:

-0.68

ARDX:

-0.23

Sortino Ratio

DNA:

-1.08

ARDX:

0.21

Omega Ratio

DNA:

0.89

ARDX:

1.03

Calmar Ratio

DNA:

-0.78

ARDX:

-0.20

Martin Ratio

DNA:

-1.09

ARDX:

-0.46

Ulcer Index

DNA:

71.34%

ARDX:

38.46%

Daily Std Dev

DNA:

113.40%

ARDX:

78.36%

Max Drawdown

DNA:

-99.10%

ARDX:

-98.45%

Current Drawdown

DNA:

-98.69%

ARDX:

-84.01%

Fundamentals

Market Cap

DNA:

$456.72M

ARDX:

$1.20B

EPS

DNA:

-$10.54

ARDX:

-$0.18

PS Ratio

DNA:

2.01

ARDX:

3.59

PB Ratio

DNA:

0.64

ARDX:

6.90

Total Revenue (TTM)

DNA:

$189.10M

ARDX:

$287.59M

Gross Profit (TTM)

DNA:

$138.44M

ARDX:

$243.60M

EBITDA (TTM)

DNA:

-$316.36M

ARDX:

$5.19M

Returns By Period

In the year-to-date period, DNA achieves a -20.16% return, which is significantly lower than ARDX's 3.75% return.


DNA

YTD

-20.16%

1M

17.89%

6M

-3.92%

1Y

-74.80%

5Y*

N/A

10Y*

N/A

ARDX

YTD

3.75%

1M

4.37%

6M

-8.84%

1Y

-16.64%

5Y*

-6.94%

10Y*

-7.58%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DNA vs. ARDX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA
The Risk-Adjusted Performance Rank of DNA is 1515
Overall Rank
The Sharpe Ratio Rank of DNA is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 1212
Sortino Ratio Rank
The Omega Ratio Rank of DNA is 1616
Omega Ratio Rank
The Calmar Ratio Rank of DNA is 66
Calmar Ratio Rank
The Martin Ratio Rank of DNA is 2525
Martin Ratio Rank

ARDX
The Risk-Adjusted Performance Rank of ARDX is 4242
Overall Rank
The Sharpe Ratio Rank of ARDX is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of ARDX is 4343
Sortino Ratio Rank
The Omega Ratio Rank of ARDX is 4343
Omega Ratio Rank
The Calmar Ratio Rank of ARDX is 4040
Calmar Ratio Rank
The Martin Ratio Rank of ARDX is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DNA vs. ARDX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Ardelyx, Inc. (ARDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for DNA, currently valued at -0.68, compared to the broader market-2.00-1.000.001.002.003.00
DNA: -0.68
ARDX: -0.23
The chart of Sortino ratio for DNA, currently valued at -1.08, compared to the broader market-6.00-4.00-2.000.002.004.00
DNA: -1.08
ARDX: 0.21
The chart of Omega ratio for DNA, currently valued at 0.89, compared to the broader market0.501.001.502.00
DNA: 0.89
ARDX: 1.03
The chart of Calmar ratio for DNA, currently valued at -0.78, compared to the broader market0.001.002.003.004.005.00
DNA: -0.78
ARDX: -0.31
The chart of Martin ratio for DNA, currently valued at -1.09, compared to the broader market-5.000.005.0010.0015.0020.00
DNA: -1.09
ARDX: -0.46

The current DNA Sharpe Ratio is -0.68, which is lower than the ARDX Sharpe Ratio of -0.23. The chart below compares the historical Sharpe Ratios of DNA and ARDX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
-0.68
-0.23
DNA
ARDX

Dividends

DNA vs. ARDX - Dividend Comparison

Neither DNA nor ARDX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DNA vs. ARDX - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum ARDX drawdown of -98.45%. Use the drawdown chart below to compare losses from any high point for DNA and ARDX. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%NovemberDecember2025FebruaryMarchApril
-98.69%
-46.00%
DNA
ARDX

Volatility

DNA vs. ARDX - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 32.07% compared to Ardelyx, Inc. (ARDX) at 16.55%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than ARDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%NovemberDecember2025FebruaryMarchApril
32.07%
16.55%
DNA
ARDX

Financials

DNA vs. ARDX - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Ardelyx, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items